Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 35 citing Richelsen: Effect of Orlistat on weight regain and cardiovascular risk factors following.... (0.09 sec) 

Weight loss larger than 10% is needed for general improvement of levels of circulating …

- eje.org
EL Madsen, A Rissanen, JM Bruun, K … - European Journal of Endocrinology, 2008 - eje.org
Results: Weight loss after VLED treatment was 14.3±4.5 kg and after 3 years
7.7±8.7 kg. Orlistat-treated subjects regained 3.9 kg less than placebo-treated
from the end of the VLED to 3 years (P=0.01). No differences were detected ...
Cited by 19 - Related articles - BL Direct - All 7 versions

Orlistat-associated adverse effects and drug interactions: a critical review


TD Filippatos, CS Derdemezis, IF Gazi, ES … - Drug Safety, 2008 - ingentaconnect.com
0114-5916/08/0001-0053/$48.00/0 © 2008 Adis Data Information BV. All rights
reserved. ... Theodosios D. Filippatos, 1 Christos S. Derdemezis, 1 Irene F.
Gazi, 1 Eleni S. Nakou, 1 ... Dimitri P. Mikhailidis 2 and Moses S. Elisaf 1
Cited by 15 - Related articles - BL Direct - All 6 versions

Obesity management: Update on orlistat


BS Drew, AF Dixon, JB Dixon - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov
Over the past 20 years obesity has become a worldwide concern of frightening
proportion. The World Health Organization estimates that there are over 400
million obese and over 1.6 billion overweight adults, a figure which is ...
Cited by 10 - Related articles - BL Direct - All 8 versions

Sibutramine: current status as an anti-obesity drug and its future perspectives


B Sharma, DC Henderson - Expert Opin. Pharmacother., 2008 - informahealthcare.com
Background: Obesity has become a global epidemic with recent estimates of > 400
million obese adults. Despite this, there are few safe and effective
pharmacological interventions for obesity. Sibutramine is a weight loss ...
Cited by 5 - Related articles - All 6 versions

Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial


M Svendsen, A Rissanen, B Richelsen, S … - Obesity, 2008 - nature.com
* Department of Psychiatry and Health Behavior, Augusta, Georgia. ...
Georgia Prevention Institute, Department of Pediatrics, Augusta, Georgia. ...
‡ Department of Biostatistics, Medical College of Georgia, Augusta, Georgia.
Cited by 5 - Related articles - All 2 versions

Randomized clinical trials of weight loss maintenance: a review


MW Turk, K Yang, M Hravnak, SM Sereika, LJ … - Journal of Cardiovascular Nursing, 2009 - journals.lww.com
The problem of overweight and obesity has reached epidemic proportions in the
United States and globally, and the high prevalence is due in part to the
recidivism associated with weight loss treatment. Approximately one-third ...
Cited by 6 - Related articles - All 5 versions

Orlistat in the prevention of diabetes in the obese patient


MC Mancini, A Halpern - Vascular Health and Risk Management, 2008 - pubmedcentral.nih.gov
There has been an increase in the concern about preventing type 2 diabetes
mellitus (T2DM), a disease with great and increasing prevalence. The prevalence
of obesity, physical inactivity, Western processed diet, important risk ...
Cited by 3 - Related articles - BL Direct - All 8 versions

American College of Endocrinology Pre-Diabetes Consensus Conference: Part One


ZT Bloomgarden - Diabetes care, 2008 - care.diabetesjournals.org.p.angrylapdog.com
Michael Stern (San Antonio, TX) opened the conference by discussing approaches
to identifying pre-diabetes, noting that, of course, there is always
pre-diabetes before diabetes and that, of course, diabetes is associated ...
Cited by 2 - Related articles - All 11 versions

Effect of antiobesity medications in patients with type 2 diabetes mellitus.


S Choussein, AA Makri, CC Frangos, ET … - Diabetes, Obesity & Metabolism, 2009 - pt.wkhealth.com
Obesity is considered as a major health problem, as its prevalence continuously
rises worldwide. One of the common health consequences of obesity is type 2
diabetes mellitus. Therefore, antiobesity management is a prerequisite in ...
Cited by 2 - Related articles - All 6 versions

Pharmacotherapy for obesity


LM Neff, LJ Aronne - Current Atherosclerosis Reports, 2007 - Springer
Obesity is a chronic metabolic disorder that affects one third of American
adults. Modest weight losses of just 5% to 10% of body weight, which are
achievable with lifestyle modification and pharmacotherapy, can lead to ...
Cited by 2 - Related articles - BL Direct - All 2 versions


Result Page: 

1

2

3

4

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google